Development of diagnostic device to differentiate between bipolar and unipolar depression

点击翻译按钮获取中文摘要

Bipolar disorder affects 2.4m people in the UK alone and has an estimated prevalence of around 2% globally, yet 40% of patients with bipolar disorder are misdiagnosed with depression and it takes an average of 7.5 years for the correct diagnosis to be reached. This leads to ineffective treatments, increased suicide risk, antidepressant-induced mania and higher healthcare costs, as well decreased quality of life for patients and their families. The long-term mission for Psyomics is improved prevention, diagnosis and treatment of mental health conditions. Our initial focus is on improved diagnosis of bipolar disorder and depression in primary care Recent research conducted by Psyomics and the Cambridge Centre for Neuropsychiatric Research has identified key biomarkers, assessed in dried blood spots and via a digital-screening approach that can differentiate these conditions with a strong predictive performance. This project will enable Psyomics to build on these results with the aim of launching a digital-only tool to support stratification in 2019 and a two-stage digital and biological diagnostic device to improve diagnosis and clinical outcomes for patients and their families in 2020.